

1 **List of Supplemental Tables**

2 **Table S1A:** Information on all 39 CRC cell lines for proteomics data, related to Figure 1

3 **Table S1B:** Information on GIS sample mutational and MSI status, related to Figure 1

4 **Table S1C:** Information on labelling different technical replicates of samples with TMT 16-plex,
5 related to Figure 1

6 **Table S1D:** List of all quantified phosphorylation sites for technical replicates, related to Figure
7 1

8 **Table S1E:** List of all identified proteins for technical replicates, related to Figure 1

9 **Table S2A:** Phosphoproteomics data of CRC35, related to Figures 2, 3, and 4

10 **Table S2B:** Proteomics data of CRC35, related to Figures 2, 3, and 4

11 **Table S2C:** Results of the KEGG pathway analysis, related to Figure 2

12 **Table S2D:** Results of the STRING network analysis, related to Figure 2

13 **Table S3A:** List of protein–protein pairs with a positive correlation rate ($Rho \geq 0.9$) in KRAS-
14 mutant cells

15 **Table S3B:** Correlation coefficients of the top and bottom 10% protein–protein pairs

16 **Table S3C:** Functional annotation of the commonly occurring protein pairs (bottom 10% of the
17 correlation difference) (CORUM sets)

18 **Table S3D:** Functional annotation of the KRAS-specific protein pairs (top 10% of correlation
19 coefficients of differential gene pairs) (KEGG pathway sets)

20 **Table S4:** Pairwise correlation analysis of each phosphorylation level of phosphorylation sites
21 with the gene dependence scores of the corresponding phosphoproteins, related to Figure 4

22 **Table S5A:** PTM-SEA results, related to Figure 5

23 **Table S5B:** Results of the KEGG pathway analysis, related to Figure 5

24 **Table S5C:** Correlation between drug sensitivity to FDA-approved inhibitors (CTD2 cell line
25 pharmacological profiling data) and phosphorylation level of PARD3 Y378-p, related to Figure

26 5

27

28